Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Intermediate-size Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

NCT04438512 is registered in ClinicalTrials.gov with Resilient Pharmaceuticals as lead sponsor.

NCT NCT04438512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04438512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Intermediate-size Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD
Lead sponsor
Resilient Pharmaceuticals
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

post traumatic stress disorder